Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
NCT07819799Phase 1Not yet recruiting
- Sponsor
- Attovia Therapeutics
- Start
- Dec 2026
- Primary completion
- Jul 2028
01
Overview
Phase 1 trial of ATTO-1091 in ulcerative colitis (UC) (4 arms), sponsored by Attovia Therapeutics. Primary endpoints: Incidence of Adverse Events, Incidence of laboratory abnormalities and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ATTO-1091
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07819799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819799.